NEW YORK ─ Bio-Techne and Regulus Therapeutics on Wednesday announced a collaboration to support biomarker assay development and biomarker analysis for the clinical development of Regulus' RGLS4326, an autosomal dominant polycystic kidney disease (ADPKD) treatment.
Regulus has used two Bio-Techne branded product lines, ProteinSimple and Exosome Diagnostics, to help with its clinical trial patient testing, Bio-Techne said.